Skip to main content

Market Overview

aTyr Pharma Recruits Lonza As Manufacturing Partner For Cancer Therapy ATYR2810

aTyr Pharma Recruits Lonza As Manufacturing Partner For Cancer Therapy ATYR2810
  • aTyr Pharma Inc (NASDAQ: LIFE) and Lonza Group Ltd (OTCMKTS: LZAGF) have agreed to manufacture ATYR2810, aTyr's monoclonal antibody targeting Neuropilin-2 (NRP2) that is currently in preclinical development for cancer.
  • Under the terms of the agreement, Lonza will utilize its Ibex Design to manufacture material for ATYR2810.
  • The deal will cover the early stages from gene to Investigational New Drug. It will provide both drug substance and drug product to support toxicological studies in animals and early clinical development in humans.
  • The scope will include process support, including cell line development, process development, and supply chain simplification, to drug substance & product manufacturing at Lonza's Visp and Stein sites in Switzerland.
  • ATYR2810 is a fully-humanized monoclonal antibody designed to specifically and functionally block the interaction between NRP2 and one of its primary ligands, VEGF.
  • Price Action: LIFE shares are up 1.9% at $3.81 on the last check Wednesday.

Related Articles (LZAGY + LZAGF)

View Comments and Join the Discussion!

Posted-In: Briefs cancerBiotech News Penny Stocks Health Care Contracts General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at